Topic:

R&D

Latest Headlines

Latest Headlines

Mayo Clinic, Gentag partner to develop movement sensor patches

The Mayo Clinic and Gentag are partnering to develop next-generation, wireless, disposable patch sensors to enable researchers to track patient movements in order to better address conditions such as diabetes and obesity.

Chrono Therapeutics ropes in new funds from Rock Health for smoking cessation device

Chrono Therapeutics got a fresh infusion of cash from Rock Health to support development of its programmable monitoring system for smoking cessation.

Startup Alkahest inks a $50M deal for anti-aging R&D

Alkahest, a member of Johnson & Johnson's just-launched biotech incubator, signed a $50 million agreement with Spanish giant Grifols to hit the gas on its novel approach to treating neurodegeneration.

FDA grants emergency use authorization to Corgenix's fast-acting Ebola diagnostic

"This thing isn't over yet," warned President Barack Obama's Ebola czar Ron Klain in a recent interview. While recovering slowly West Africa is plagued by the epidemic and needs new tools in the ongoing battle against the disease.

Amgen launches delivery device for automatic administration of its blockbuster Neulasta

Amgen just announced the debut of the Neulasta Delivery Kit to automatically deliver the medication for infection prevention among cancer patients about 27 hours after chemotherapy, thereby ensuring compliance with the dosing instructions.

Alexion bets up to $265M on Blueprint's precision medicine platform

Rare disease magnate Alexion is aligning itself with biotech Blueprint Medicines, borrowing the company's development technology to spotlight new treatments for genetic disorders.

Merck touts a bright future in biosimilars with a stable of would-be blockbusters

Merck may trail the first movers in the coming onslaught of blockbuster biosimilars, but the pharma giant is heralding a crop of late-stage copycat treatments it believes can snag a share of the soon-to-boom market.

Ambitious cancer R&D plans may explain Merck KGaA cutbacks

Anyone looking for some perspective on Merck KGaA's recent R&D cutbacks should check out an interview CFO Marcus Kuhnert gave to CNBC. 

J&J picks the inaugural class for its Bay Area biotech incubator

Johnson & Johnson has opened the doors of its new biotech incubator, bringing in its first 10 resident startups and hoping to galvanize the next generation of life sciences innovators.

Evidence that inhaled oxytocin improves social behavior among autistic patients spurs R&D

Additional evidence that oxytocin increases eye contact among autistic patients adds urgency to the efforts of GlaxoSmithKline, OptiNose and other companies scrambling to develop an inhaled version of the "love hormone."